AEG35156 + carboplatin + paclitaxel

AEG35156 + carboplatin + paclitaxel is a combination investigational therapy evaluated in clinical trials for cancer. **AEG35156** is a second-generation antisense oligonucleotide designed to target and downregulate mRNA of the X-linked inhibitor of apoptosis protein (*XIAP*), a protein that blocks apoptosis by inhibiting caspases and is frequently overexpressed in various cancers, leading to chemoresistance[1][2][3][5]. By suppressing XIAP, AEG35156 lowers the apoptotic threshold of tumor cells, potentially enhancing the efficacy of cytotoxic agents. **Carboplatin** and **paclitaxel** are standard chemotherapy agents: carboplatin is a platinum-based DNA crosslinker, and paclitaxel is a microtubule stabilizer, interfering with mitosis. In combination, this regimen is designed to induce tumor cell death by both disabling cell division (through carboplatin and paclitaxel) and overcoming anti-apoptotic resistance mechanisms (through AEG35156). The combination has been explored in varied malignancies. AEG35156 was developed by Aegera Therapeutics, and clinical studies indicate it is generally well tolerated, with its main investigational use in relapsed or refractory acute myeloid leukemia, solid tumors, and in combination with chemotherapies including carboplatin and paclitaxel[1][2][3]. Mechanistically, the combination strategy leverages **AEG35156’s targeted anti-apoptotic action along with the broad cytotoxic effects of carboplatin and paclitaxel**.